Achmea Investment Management’s NovoCure NVCR Stock Holding History

Achmea Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,625	Closed	-$192K	–	592
2023 Q2	$192K	Hold	4,625	–	–	﹤0.01%	532
2023 Q1	$278K	Hold	4,625	–	–	0.01%	488
2022 Q4	$318K	Hold	4,625	–	–	0.01%	522
2022 Q3	$352K	Hold	4,625	–	–	0.01%	526
2022 Q2	$321K	Hold	4,625	–	–	0.01%	520
2022 Q1	$383K	Buy	+4,625	New	+$341K	0.01%	538
2021 Q4	–	Sell	-4,625	Closed	-$538K	–	453
2021 Q3	$538K	Sell	4,625 -293	-6%	-$44.3K	0.02%	513
2021 Q2	$1.09M	Buy	4,918 +465	+10%	+$90.5K	0.04%	399
2021 Q1	$589K	Hold	4,453	–	–	0.02%	483
2020 Q4	$771K	Buy	+4,453	New	+$609K	0.03%	427

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Achmea Investment Management's NVCR Position: Q3 2023 in Review

Achmea Investment Management sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 4,625 shares — an estimated $192K sold.

Achmea Investment Management first reported a position in NVCR in Q4 2020 and held it in 10 quarters. The position peaked at $1.09M in Q2 2021. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

Achmea Investment Management reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
Achmea Investment Management sold 4,625 NovoCure shares in Q3 2023, an estimated $192K.
Achmea Investment Management first reported a position in NovoCure in Q4 2020 and held it in 10 quarters.
Achmea Investment Management's NovoCure position peaked at $1.09M in Q2 2021.
226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Achmea Investment Management's 13F filing for Q3 2023, filed 6 Nov 2023.